- Home
- IGC vs PTN Comparison
IGC vs PTN Comparison
Compare IGC & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- PTN
- Stock Information
- Founded
- IGC 2005
- PTN 1986
- Country
- IGC United States
- PTN United States
- Employees
- IGC N/A
- PTN N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- IGC Health Care
- PTN Health Care
- Exchange
- IGC Nasdaq
- PTN Nasdaq
- Market Cap
- IGC 29.4M
- PTN 25.4M
- IPO Year
- IGC N/A
- PTN 1993
- Fundamental
- Price
- IGC $0.33
- PTN $0.91
- Analyst Decision
- IGC Strong Buy
- PTN Strong Buy
- Analyst Count
- IGC 2
- PTN 1
- Target Price
- IGC $3.75
- PTN $17.00
- AVG Volume (30 Days)
- IGC 380.9K
- PTN 348.6K
- Earning Date
- IGC 02-12-2025
- PTN 02-13-2025
- Dividend Yield
- IGC N/A
- PTN N/A
- EPS Growth
- IGC N/A
- PTN N/A
- EPS
- IGC N/A
- PTN N/A
- Revenue
- IGC $1,183,000.00
- PTN $2,384,113.00
- Revenue This Year
- IGC N/A
- PTN N/A
- Revenue Next Year
- IGC $13.38
- PTN N/A
- P/E Ratio
- IGC N/A
- PTN N/A
- Revenue Growth
- IGC N/A
- PTN N/A
- 52 Week Low
- IGC $0.27
- PTN $0.68
- 52 Week High
- IGC $0.91
- PTN $5.22
- Technical
- Relative Strength Index (RSI)
- IGC 41.18
- PTN 39.62
- Support Level
- IGC $0.31
- PTN $0.86
- Resistance Level
- IGC $0.37
- PTN $0.97
- Average True Range (ATR)
- IGC 0.02
- PTN 0.11
- MACD
- IGC -0.00
- PTN -0.03
- Stochastic Oscillator
- IGC 28.17
- PTN 10.65
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.